New treatments have changed the face of managing hemophilia with an inhibitor, columnist Cazandra Campos-MacDonald writes.

Biologics are also used in hematologic conditions such as hemophilia A and B. Factor replacement therapies and newer agents like emicizumab (Hemlibra) are used to reduce bleeding episodes. In patients ...

and Hemlibra (emicizumab) for haemophilia. Diagnostic led the charge, rising 24% to CHF 5.3 billion, but pharma also had a solid start to the year with a 6% gain to CHF 11.2 billion. Ocrevus rose ...

At the moment, patients are given regular injections with Factor VIII replacement therapies, or antibody therapies like Roche's big-selling antibody Hemlibra (emicizumab), which works via a ...